scholarly journals POS-203 MULTIPLE MYELOMA AND RENAL IMPAIREMENT :DESCRIPTIVE STUDY ABOUT 53 CASES IN NEPHROLOGY DEPARTEMENT

2021 ◽  
Vol 6 (4) ◽  
pp. S85-S86
Author(s):  
N. Nawres ◽  
B.A. Narjes ◽  
M. Sanda ◽  
G. Yosra ◽  
Z. Dorsaf ◽  
...  
2020 ◽  
Vol 29 (2) ◽  
pp. 103-110
Author(s):  
Clare Horgan Cuffe ◽  
Mary B Quirke ◽  
Catherine McCabe

Background: Multiple myeloma is a B-cell haematological malignancy characterised by uncontrolled plasma cell proliferation. Patients with the disease often undergo periods of remission followed by multiple relapses. Understanding patients' experience of living with this chronic condition is key to providing effective patient-centred care. Aims: This qualitative descriptive study explored the experiences of patients living with multiple myeloma. Methods: A purposive sample of 6 patients was used. Data were collected using in-depth unstructured interviews and analysed using Colaizzi's (1978) thematic framework. Findings: The emergent themes included: information and communication; treatment and symptom burden; the importance of support from family/friends and professional help; psychosocial elements of survivorship. Conclusion: The complex symptoms of multiple myeloma need to be treated holistically to manage the unpredictable nature of this disease.


2012 ◽  
Vol 11s1 (2) ◽  
pp. 444-447
Author(s):  
Luiz Fernandes Gonçalves Fialho ◽  
Patricia dos Santos Claro Fuly

2019 ◽  
Vol 85 ◽  
pp. S42
Author(s):  
O. Ibtissem ◽  
M. Hacene ◽  
G. Sabiha ◽  
G. Farida

2013 ◽  
Vol 93 (1) ◽  
pp. 141-145 ◽  
Author(s):  
Noha M. El Husseiny ◽  
Neemat Kasem ◽  
Hamdy Abd El Azeeim ◽  
Mervat W. Mattar

2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.


2010 ◽  
Vol 20 (2) ◽  
pp. 42-50 ◽  
Author(s):  
Laura W. Plexico ◽  
Julie E. Cleary ◽  
Ashlynn McAlpine ◽  
Allison M. Plumb

This descriptive study evaluates the speech disfluencies of 8 verbal children between 3 and 5 years of age with autism spectrum disorders (ASD). Speech samples were collected for each child during standardized interactions. Percentage and types of disfluencies observed during speech samples are discussed. Although they did not have a clinical diagnosis of stuttering, all of the young children with ASD in this study produced disfluencies. In addition to stuttering-like disfluencies and other typical disfluencies, the children with ASD also produced atypical disfluencies, which usually are not observed in children with typically developing speech or developmental stuttering. (Yairi & Ambrose, 2005).


2000 ◽  
Vol 111 (4) ◽  
pp. 1118-1121 ◽  
Author(s):  
A. Bellahcene ◽  
I. Van Riet ◽  
C. de Greef ◽  
N. Antoine ◽  
M. F. Young ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document